Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-gamma.
We investigated the influence of the combined use of sizofiran, a beta-1,3-glucan and a recombinant interferon-gamma (rIFN-gamma) upon biological activities of peritoneal macrophages (M phi). The number of peritoneal M phi and the production of cytokines (interleukin-1 beta, interferon-gamma and tumor necrosis factor) was increased by the combined treatment. Fully activated peritoneal M phi based on the increased number of elongated pseudopods were observed by electromicroscope. Sizofiran seems to assure a sufficient supply of M phi to kill tumor cells in the peritoneal cavity and co-administered rIFN-gamma seems to directly stimulate the accumulated M phi in addition to its direct cytotoxicity against tumor cells. This combination therapy may be a step to the prevention of the recurrence of gynecological malignancies including ovarian cancer, after a negative second-look laparotomy.